BBAL New York Health Care Inc (CE)

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

SEC File Number 001-12451
CUSIP Number 649487204

|X| Form 10-K |_| Form 20-F |_| Form 11-K |_| Form 10-Q |_| Form N-SAR
|_| Form N-CSR

For the period ended: December 31, 2007

|_| Transition Report on Form 10-K
|_| Transition Report on Form 20-F
|_| Transition Report on Form 11-K
|_| Transition Report on Form 10-Q
|_| Transition Report on Form NSAR

For the transition period ended: ________________

Read attached Instruction Sheet Before Preparing Form. Please Print or Type.

NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification related to a portion of the filing checked above, identify
the item(s) to which notification relates: _____________________________________
____________________________________________________________.

PART I-REGISTRANT INFORMATION

Full name of Registrant: NEW YORK HEALTH CARE, INC.
 --------------------------
Former name if Applicable:
Address of Principal Executive Office
(Street and Number): 1850 McDonald Avenue
 --------------------------
City, State and Zip Code: Brooklyn, New York 11223
 --------------------------

PART II-RULE 12B-25(B) AND (C)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

|_| (a) The reasons described in detail in Part III of this form could not
 be eliminated without unreasonable effort or expense

|X| (b) The subject annual report, semi-annual report, transition report of
 Forms 10-K, 10-KSB, 20-F, 11-K or Form N-SAR, or portion thereof
 will be filed on or before the 15th calendar day following the
 prescribed due date; or the subject quarterly report or transition
 report on Form 10-Q, 10-QSB, or portion thereof will be filed on or
 before the fifth calendar day following the prescribed due date; and

|_| (c) The accountant's statement or other exhibit required by Rule
 12b-25(c) has been attached if applicable.

PART III-NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-QSB, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

The Company has not been able to compile the requisite financial data and other narrative information necessary to enable it to have sufficient time to complete the Company's Annual Report on Form 10-K by March 31, 2008, the required filing date, without unreasonable effort and expense.

PART IV-OTHER INFORMATION

(1) Name and Telephone Number of person to contact in regard to this notification

Stewart W. Robinson 718 375-6700
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). |X| Yes |_| No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? |X| Yes |_| No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Management anticipates that the loss for the year ended December 31, 2007 will approximate $(900,000) as compared to the loss for the immediately preceding year of approximately $(3,800,000), a decrease of approximately $(2,900,000). Management believes that the decrease in the loss in 2007 was primarily because of the scaling back of the operations of the BioBalance segment, resulting in overall reductions of expenses of approximately $2,900,000 and a decrease in general & administrative expenses in the health care segment of approximately $700,000, offset by an anticipated charge by the BioBalance segment of approximately $700,000 for the impairment of an intangible asset.

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 28, 2008 By: /s/ Stewart W. Robinson
 ----------------------------------
 Stewart W. Robinson
 Chief Financial Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL
VIOLATIONS (SEE 18 U.S.C. 1001).

Grafico Azioni New York Health Care (CE) (USOTC:BBAL)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni New York Health Care (CE) (USOTC:BBAL)
Storico
Da Giu 2023 a Giu 2024